Evidence map›Paper›PMID 32511434›Full record

ArticlemedRxiv : the preprint server for health sciences2020

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.

Angkana T Huang, Bernardo Garcia-Carreras, Matt D T Hitchings, Bingyi Yang, Leah C Katzelnick, Susan M Rattigan, Brooke A Borgert, Carlos A Moreno, Benjamin D Solomon, Isabel Rodriguez-Barraquer and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 342 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Angkana T HuangDepartment of Biology, University of Florida, USA.
Bernardo Garcia-CarrerasDepartment of Biology, University of Florida, USA.
Matt D T HitchingsDepartment of Biology, University of Florida, USA.
Bingyi YangDepartment of Biology, University of Florida, USA.
Leah C KatzelnickDepartment of Biology, University of Florida, USA.
Susan M RattiganDepartment of Biology, University of Florida, USA.
Brooke A BorgertDepartment of Biology, University of Florida, USA.
Carlos A MorenoDepartment of Biology, University of Florida, USA.
Benjamin D SolomonNational Human Genome Research Institute, National Institutes of Health, USA.
Isabel Rodriguez-BarraquerDivision of HIV, ID, and Global Medicine, University of California, San Francisco, USA.
Justin LesslerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA.
Henrik SaljeDepartment of Genetics, University of Cambridge, Cambridge, United Kingdom.
Donald BurkeDepartment of Epidemiology, University of Pittsburgh, USA.
Amy WesolowskiDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA.
Derek A T CummingsDepartment of Biology, University of Florida, USA.
University of Florida · USJohns Hopkins University · USNational Institutes of Health · USUniversity of California, San Francisco · USUniversity of Cambridge · GBUniversity of Pittsburgh · US

Funding

Medical Genomics Unit Analytic ProjectsZIAHG200405 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SOLOMON, BENJAMIN · 2020 to 2025
$4.4M
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISKR01AI114703 · NIAID · UNIVERSITY OF FLORIDA · PI CUMMINGS, DEREK A · 2015 to 2019
$3.6M
Disease Emergence and Elimination: Using Mobility Data to Inform Spatial Disease DynamicsDP2LM013102 · NLM · JOHNS HOPKINS UNIVERSITY · PI WESOLOWSKI, AMY · 2018 to 2018
$2.5M
NIAID NIH HHS R01 AI114703NLM NIH HHS DP2 LM013102
6 · The paper itself

Abstract

The duration and nature of immunity generated in response to SARS-CoV-2 infection is unknown. Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARSCoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The timescale of protection is a critical determinant of the future impact of the pathogen. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV-1, MERS-CoV and human endemic coronaviruses (HCoVs). We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research.

Identifiers

PMID32511434
PMCPMC7217088
OpenAlexW3017268399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.